Status:
COMPLETED
Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer
Lead Sponsor:
Instituto do Cancer do Estado de São Paulo
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Treatment for patients with high-risk breast cancer diagnoses is based on chemotherapy drugs with side effects. Dexamethasone is a drug that is part of the arsenal of pre-chemotherapy medications to p...
Detailed Description
Treatment for patients with diagnoses of high-risk breast cancer is based on chemotherapy drugs such as anthracyclines and taxanes and its main side effects described are cardiac toxicity and hypersen...
Eligibility Criteria
Inclusion
- Patients from the oncology services of ICESP and its Osasco unit.
- Over 18 years of age.
- Diagnosed with breast cancer who will be treated with an ACT Icesp scheme in the setting with curative intent (neoadjuvant and adjuvant).
Exclusion
- Patients with significant cognitive impairment that prevents the questionnaire from being applied.
- Patients who are not fluent in Portuguese, or illiterate, who did not sign the ICF.
- ECOG 3 and KPS \<70%.
- Metastatic patients, with the presence of other important morbidities that may interfere with laboratory findings.
- Patients with chronic use of steroidal and non-steroidal anti-inflammatory drugs.
Key Trial Info
Start Date :
March 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2022
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04350229
Start Date
March 27 2020
End Date
June 20 2022
Last Update
October 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanessa Scontre
São Paulo, São Paulo, Brazil, 01246000